Isx2006 clinical case presentation

Topical Healing Botanical Preparation
Human clinical case studies
involving various lesion-tissue
types and comprising skin,
mucous membranes, subcutaneous
tissue, muscle and bone tissue
Dr. Rodolfo Salas Auvert
PROPIETARY MATERIAL OF DR. RODOLFO SALAS AUVERT

ISX2006 is a botanical preparation of selected natural
ingredients combined to generate synergistic and potentiated
beneficial effects for lesion and tissue repair. The following
presentation-results correspond with human clinical studies.
Cases presented comprise straight forward evolution, simple
and complex clinical cases with torpid progress, given lesion
nature, tissue involved and patient medical-condition.
Composition: Plantago major, Curcumin Luonga and β-(1-4)-linked D-glucosamine
(Chitosan).
Formulation: Unguent
Posology: External application to cleansed lesion area.
Therapeutics: Application to skin and mucous membranes.

Informed Consented Patients
The cases presented herein correspond with (informed consented) patients of
different age and gender, hospitalized, in-house, outpatients; and with tissue-lesions
of various nature, anatomical location, severity and etiology. The patient-lesions
treated topically with preparation ISX2006 at least once a day after wound cleansing.
The treatment goal to stimulate wound cicatrization-epithelialization by second
intention, lesion size reduction or tissue quality improvement for an early
skin graft. No antibiotic or additional co-therapy used.

Lesion Type Disease No. Cases Results
Diabetes
Ulcer Type-I 11 Satisfactory
Ulcer Type-II 27 Satisfactory
Surgical Amputation 15 Satisfactory
Burns
Thermal 2nd degree 12 Satisfactory
Thermal 3rd degree 8 Satisfactory
Ulcer Trophic 26 Satisfactory
Ulcer Ischaemic 18 Satisfactory
Plantar mal Leprosy 5 Partial results
Necrosis Ischaemic 3 Satisfactory
Necrosis Iatrogenic 1 Satisfactory
Skin Necrosis Skin Necrolysis 1 Satisfactory
Ulcer Neoplastic 2 Satisfactory
Surgical Skin Graft 12 Satisfactory
Inflammatory Hemorrhoids 35 Satisfactory
Total 176
CLINICAL CASE STUDY OF 176 INFORMED CONSENTED PATIENTS
WITH VARIOUS LESION TYPES TREATED WITH ISX2006
Note: Other lesion types
treated but not accounted
for in this report comprise;
chapped lips and skin,
Insect bytes, minor skin
irritation, solar burn, tongue,
vaginal and oral mucosa
lesions, ear lesions.

Overall study results of patients with hemorrhoidal
lesions topically with preparation ISX2006
Medical
Assessment Self-Assessment
Percent Percent
Improved 78 95
appearance
Inflammation 80 90
Reduction
Pain reduction NA 97
A reduced study was undertaken to establish the potential application of preparation
ISX2006 on the symptoms and resolution of 35 patients with hemorrhoidal lesions. Two
types of lesions treated: external and internal. Internal lesions attended with the aid of a
cannula. The preparation applied twice-trice a day after anal cleansing. Progress evaluated
based on medical and patient self-assessment given improved visual appearance on
external lesions, inflammation, and pain reduction.
Disease: Enteric-Mucosal
Lesion type: Hemorrhoidal tissue
Day 0 Day 5
Day 7PROPIETARY MATERIAL OF DR. RODOLFO SALAS AUVERT

Disease: Diabetic
Lesion type: Ulcer and Surgical lesions
Study: Document diabetic lesions healing potential of preparation ISX2006
through a double-blind clinical investigation involving 31 (informed
consented) patients (11 type-I and 20 type-II diabetic patients) with
paired lesions of different size and leg location.
Goal: Study the effect of ISX2006 preparation on chronic leg lesions according
with disease classification, lesion size and healing rate. Two groups accounted
for: Test (ISX2006 treated) and Placebo (Vaseline treated).
Treatment: Preparation applied topically once a day after conventional
wound cleansing procedure. No antibiotics co-therapy involved. Wound
dressing applied when needed-required.
Data analysis: Wound photographic record established regarding measured
lesion size and clinical evolution.
Note: No adverse or allergic reaction reported.

1 2 3 4 5 6 7 8 9 10 11
Size cm2 2 3,8 1,5 3,1 2,6 3,6 4,2 1,1 1,7 2,5 2,4
Time-days 20 22 15 21 19 21 33 8 10 21 18
mm2/day 1,00 1,73 1,00 1,48 1,37 1,71 1,27 1,38 1,70 1,19 1,33
0
5
10
15
20
25
30
35
cm2,days,mm2
Diabetic Type-1 lesion evolution data
after treatment with ISX2006
Test Avrg
Size cm2 2.59
Time 18.91
mm2/day 1.38
Basic Statistics MAX MIN Avrg
Lesion size limits (cm2) 4.20 1.10 2.59
Healing time-Days 33.00 8.00 18.91
Healing rate mm2/day 1.73 1.00 1.38
Clinical Case: Double-blind diabetic type-I ulcer patient
evolution process, treated with ISX2006

1 2 3 4 5 6 7 8 9 10 11
Size cm2 0,7 1,8 3,5 1,1 0,5 2,3 3,9 0,5 2 0,6 3,1
Time-days 21 42 56 22 29 37 41 80 15 11 69
mm2/day 0,33 0,43 0,63 0,50 0,17 0,62 0,95 0,06 1,33 0,55 0,45
0
10
20
30
40
50
60
70
80
90
cm2,days,mm2
after treatment with placebo
Placebo Avrg
Size cm2 1.82
Time 38.45
mm2/day 0.55
Clinical Case: Double-blind diabetic type-I ulcer patient
evolution process, treated with placebo (Petrolatum).

MAX MIN Avrg
Lesion size limits
(cm2)
4,20 1,10 2,59
Healing time-Days 33,00 8,00 18,91
Healing rate mm2/day 1,73 1,00 1,38
0,00
5,00
10,00
15,00
20,00
25,00
30,00
35,00
cm2,Days,mm2/day
Diabetic Type-1 lesion healing
statistics comparison-Test
MAX MIN Avrg
Lesion size limits
(cm2)
3,90 0,50 1,82
0,00
10,00
20,00
30,00
40,00
50,00
60,00
70,00
80,00
90,00
cm2,Days,mm2/day
statistics comparison-Placebo
Clinical Case: Comparison analysis of double-blind diabetic type-I
patient-ulcer evolution process, treated with ISX2006 and placebo

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Size cm2 5,3 4,6 1,8 2,4 1 8,6 3,2 1,6 3,3 0,6 0,9 2,9 5,6 0,7 2,7 4,3 6,9 0,6 0,9 2,8
Time-Days 28 25 12 18 5 38 15 7 19 5 7 25 23 9 24 36 48 7 12 11
mm2/day 1,8 1,8 1,5 1,3 2,0 2,2 2,1 2,2 1,7 1,2 1,2 1,1 2,4 0,7 1,1 1,1 1,4 0,8 0,7 2,5
0
10
20
30
40
50
60
cm2,days,mm2
after treatment with ISX2006
Test Avrg
Size cm2 3.04
Time 18.70
mm2/day 1.59
Clinical Case: Double-blind diabetic type-II patient
ulcer evolution process, treated with ISX2006
PROPIETARY MATERIAL OF DR. RDOLFO SALAS AUVERT

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Size cm2 1,6 3,8 2,8 1,9 0,4 1,2 2,3 0,9 2,1 1,1 0,7 1,4 2,5 1,8 0,7 1,9 4 1,1 0,4 0,9
Time-days 36 51 42 67 7 22 38 45 63 35 23 68 55 58 29 75 68 75 36 12
mm2/day 0,4 0,7 0,6 0,2 0,5 0,5 0,6 0,2 0,3 0,3 0,3 0,2 0,4 0,3 0,2 0,2 0,5 0,1 0,1 0,7
0
10
20
30
40
50
60
70
80
cm2,days,mm2
after treatment with placebo
Basis Statistics MAX MIN Avrg
Placebo Avrg
Size cm2 1.68
time 45.25
mm2/day 0.40
Clinical Case: Double-blind diabetic type-II patient ulcer
evolution process, treated with placebo (Petrolatum).

MAX MIN Avrg
Lesion size limits
(cm2)
8,60 0,60 3,04
0,00
10,00
20,00
30,00
40,00
50,00
60,00
cm2,Days,mm2/day
statistics comparison-Test
MAX MIN Avrg
Lesion size limits
(cm2)
3,80 0,40 1,68
0,00
10,00
20,00
30,00
40,00
50,00
60,00
70,00
80,00
cm2,Days,mm2/day
statistics comparison-Placebo
Clinical Case: Comparison analysis of double-blind diabetic type-II
patient ulcer evolution process, treated with ISX2006 and placebo

Crossed double-blind diabetic type-I case study: patient with paired lesions on leg and foot,
treated with ISX2006 and placebo. Ankle lesion repair presented herein. (next case-slide
same patient)
Day 0-ISX2006 Day 20-ISX2006
Clinical Case: Diabetic type-I (Double blind)
L-foot
L-foot
INFORMED CONSENTED PATIENT

Crossed double-blind diabetic type-I patient study with paired lesion on leg and foot, treated with
ISX2006 and placebo. R-leg lesion placebo treated (Petrolatum) for 26-days with no change.
Following ISX2006 lesion treatment for 21-days and complete healing at 36-days.
Day 26-Placebo
Day 0-ISX2006 Day 21-ISX2006 Day 36-ISX2006
Clinical Case: Diabetic type-I (Double bind)
Day 0-PlaceboR-leg
INFORMED CONSENTED PATIENTPROPIETARY MATERIAL OF DR. RODOLFO SALAS AUVERT

Diabetic type-I patient-
amputee with lesion on
left-leg (stump) treated
with ISX2006
Patient-Case: stump lesion, 3 month (hospitalized patient)
Day 0
Day 3
Day 21
Day 46
Clinical Case: Diabetic type-I patient

Diabetic type-II
patient with lesion
on R-foot external
border, treated with
ISX2006.
Day 0Lesion age: 2 yr
Day 03
Day 06
Day 16
Clinical Case: Diabetic type-II patient
R-lateralfoot

Patient-Case: foot stump lesion, 2 month (out patient)
Day 0 Day 9 Day 16
INFORMEDCONSENTEDPATIENT

Day 62Day 0 Day 78
Patient-Case: foot lesion after surgical cleanup and fingers amputation
Cont.

Day 0 Day 92

Day 0 Day 67

Clinical Case: Vascular-Venous Stasis
Lesion type: Ulcer

A 2-yr venous stasis ulcerated lesion on a type-II diabetic patient, topically treated with
ISX2006. Inner R-malleolar area.
Day 0 Day 35 Day 68
Day 0 Day 35 Day 68
Clinical Case: Full thickness venous ulcer

Day 0 Day 0 Day 86 Day 86
A 10 yr venous stasis lesion on a 86-yr old female patient.
Goal: size reduction
Clinical Case: Ulcer (venous stasis)

Hypertensive female patient with a 32 yr
venous stasis ulcer. Lesion size 2x2x3¨.
Right inner supra-malleolar area.
Day 07
Day 45
Day 156
Clinical Case: Full-thickness ulcer (venous stasis)
R-lower leg

Clinical Case: Vascular-Ischemic
Lesion type: Ulcer

A 3-yr pressure
ulcer lesion on a
patient with
transverse myelitis,
and treated with
ISX2006. R-
ischium.
Initial lesion size:
depth 25 cm x 2.3
cm diam.
Day 0
Day 120
Day 120Day 0
Day 143
Day 153
Day 143 Day 153
Clinical Case: Ulcer (Pressure-Ischemic)
R-ischium

A 1-yr hospitalized quadriplegic patient with a T-4 lesion, and multiple ischemic ulcerated full-
thickness lesions; comprising dermal, subcutaneous, muscle and bone exposure. Treatment
goal: lesion size reduction by 2nd intention to proceed with skin grafts.
Day 0
Day 04
Day 23
Day 66
Day 91
Clinical Case: Ulcer (pressure-ischemic)

Clinical Case: Iatrogenic necrosis
Lesion type: Ulcer

A 28-day lateral R-leg iatrogenic lesion on a hospitalized patient caused by oily intramuscular
injection. Topically treated with ISX2006. Goal: reduce lesion size and improve tissue quality
for free-skin graft surgical procedure. Note: lesion improved irrigation.
Day 0
Day 0
Day 03
Day 03
Day 27
Day 07 after skin graft
Day 27
Clinical Case: Ulcer (iatrogenic)
Lateral R-leg

Disease: Neoplastic
Lesion type: Ulcer

Day 0 Day 10 Day 30
A recurrent
9-month
basocellular
Neoplasm ulcer-
lesion on left
supraciliary
area. Topically
treated with
ISX2006. Goal:
lesion size
reduction by 2nd
intention and
improve lesion
bed tissue
quality for
potential free-
skin graft
surgical
procedure.
Three prior
surgical
resections
Clinical Case: Ulcer (neoplasic)

Female patient with a prior 2-yr cutaneous lymphoma and tumor lesion, and ulcer lesion after
irradiation. Lesion size: 4“ diam x 2“ depth. Goal: Lesion healing by second intention.
Day 0
Day 0
Day 180Day 52
Day 52 Day 180
Day 302
Day 302
Clinical Case: Ulcer (Post-radiation lesion)

Clinical Case: Infectious
Lesion type: Ulcer

Day 0
A 24-yr perforating plantar mal on a lepromatous leprosy patient presenting distal nerve ending obliteration and
microangiopathy (Hansen’s disease). Patient locally treated with ISX2006. Goal: lesion size reduction and tissue
quality improvement for free-skin graft surgical procedure. No further changes documented after 263 days.
Note: tissue vascularization and remodeling
Day 0
Day 91
Day 91
Day 119
Day 119
Day 190
Day 190
Day 119
Day 119
Day 263
Day 263
Clinical Case: Ulcer (Hansen´s plantar mal)

Clinical Case: Toxic Epidermal Necrolysis
Lesion type: Skin Necrosis

Critical care patient with massive Toxic Epidermal Necrolysis
(TEN), topically treated with ISX2006 unguent and occlusive
dressing.
Day 0
Day 0
Day 0
Day 30 Day 30
Lowerbackdetail
Front BackFront
Front
Back
Day 0

Critical care patient with
massive cutaneous lysis
(Toxic Epidermal
Necrolysis) treated
topically with ISX2006
unguent and occlusive
dressing.
Day 0 Day 0
Day 30 Day 30Front
Back
Front
Back
LESION PHOTO DETAILS

Clinical Case: Water vapor burn
Lesion type: Tissue damage and Necrosis

Clinical Cases: 2nd (2AA) degree boiling (water) liquid burn
Male patient face burn 2AA with hot water vapor, treated with ISX2006.

Day 0 Day 3
Day 7 Day 15
Male patient face
burn 2AA with hot
water vapor, treated
with ISX2006.
Clinical Case: 2nd (2AA) degree boiling (water) liquid burn

Male patient face
burn 2AA with hot
water vapor,
treated with
ISX2006.
Clinical Cases: 2nd (2AA) degree boiling (water) liquid burn

Clinical Case: 2nd (2BB) degree boiling liquid burn
Male patient L-
ventral forearm
burn 2AA with hot
water vapor,
treated with
ISX2006.

Clinical Cases: 2nd (2BB) degree boiling liquid burn
Male patient L-
ventral forearm
burn 2AA with hot
water vapor,
treated with
ISX2006.

Clinical Case: 2nd (2BB) degree (water) boiling liquid burn
Boiling liquid burn lesion with a 4-day evolution.
0-day treatment.
Boiling liquid burn lesion with a 4-day
Evolution and a 5-day treatment.
Boiling liquid burn lesion with a 4-day evolution
and 20-day treatment. Complete case.

Clinical Case: 2nd (2AB) degree (water) boiling liquid burn
Boiling liquid burn with 10-day evolution.
0-day treatment.
1-day treatment.
10-day treatment.
Male patient R-Dorsal upper leg burn 2AA
with hot water vapor, treated with
ISX2006.

Clinical Case: 2nd (2AB) degree boiling liquid burn
Boiling liquid burn with 10-day
evolution. 07-day treatment
evolution. 90-day treatment.
Male patient R-Dorsal upper leg burn 2AA with hot water vapor, treated with ISX2006.
PROPIETARYMATERIALOFDR.RODOLFOSALASAUVERT

Clinical Case: 2nd (2BB) degree boiling liquid burn
Male patient ventral thorax-ventral burn 2AA
With hot water vapor, treated with ISX2006.

Clinical Case: 2nd (2AB) degree mayor burn, butane gas explosion
Methane gas explosion burn, 1-day
evolution. 0-day treatment. Body
surface burn 60 %. 2ABA+2ABB
Methane gas explosion burn, with
1-day evolution. 3-day treatment.
Body surface burn 60 %. 2ABA+2ABB

Clinical Case: 2nd (2AA) degree (water) boiling liquid burn
Water vapor burn on R-arm and
chest, 1-day evolution: 2ABA. 0-day
treatment.
treatment.
treatment.
treatment.
treatment.

Clinical Case: 2nd (2BB) degree gasoline flash burn
Gasoline combustion burn, 50 % body
surface lesion, 2ABB, involving trunk and
legs, 4-day evolution. 0-day treatment.

Clinical Case: 2nd (2BB) degree (liquid asphalt) burn
4-devolution,0-dtreatment
R-forearm molten asphalt burn, 2ABB

Clinical Case: 2nd (2BB) degree (liquid paint) burn
Boiling paint burn on legs, 2ABB

Clinical Case: 2nd (2AA) degree (water) boiling liquid burn
Male patient, water vapor burn on R-external infra-malleolus
10-dayevolution.00-daytreatment

Clinical Case: Iatrogenic (Surgical)
Lesion type: Tissue graft (donor & receptor site)

Male patient dorsal R-leg in grand burn patient after
methane gas explosion. Prior skin graft donor zone.
00-day treatment 00-day treatment after
graft removal
7-day treatment
Clinical Cases: 2nd (2BB)/3rd (3AA) degree gas flash burn

Male patient dorsal R-leg in grand burn patient after
methane gas explosion. Prior skin graft donor zone.
00-day treatment 4-day treatment
Clinical Case: 2nd (2BB)/3rd (3AA) degree gas flash burn

Clinical Case: 2nd (2BB)/3rd (3AA) degree gas flash burn
R-thigh dorsum after
dermatome and graft
Donation, 00-day
treatment.
dermatome and graft
Donation, 6-day
treatment.
dermatome and graft
Donation, 8-day
treatment.

Clinical Case: Iatrogenic
Lesion type: Post-surgical tissue necrosis

Clinical Cases: Bilateral post-mammary augmentation peri-areolar
necrosis
Photographic clinical evolution sequence of nipple-areolar necrosis
sequence during topical treatment with ISX2006. Day-0 before necrectomy

Clinical Case: Bilateral post-mammary augmentation peri-areolar
necrosis
sequence during topical treatment with ISX2006. L-Breast. After necrectomy.

necrosis
sequence during topical treatment with ISX2006. R-Breast. After necrectomy.
Note: high rate tissue epithelization-recuperation cm/day

necrosis
Photographic clinical evolution sequence of nipple-areolar sequence
before-after topical treatment with ISX2006. After necrectomy.

necrosis
during topical treatment with ISX2006. R-Breast.

necrosis
during topical treatment with ISX2006. L-Breast.
PROPIETARYMATERIALOFDR.RDOOLFOSALASAUVERT

Clinical Case: Post-surgical dehisence after compound tibia fracture.
Left leg. Topical treatment with ISX2006, cont.

Clinical Case: Post-surgical dehisence after compound tibia fracture.
Left leg. Topical treatment with ISX2006.

1. Promotes tissue granulation-epithelization of various
wound types and severity.
2. Healing effect can be extended to mucous membranous, skin,
subcutaneous tissue, muscle and bone.
3. Generates local vasodilation and increased blood irrigation
4. Non-steroidal anti-inflammatory activity.
5. Minimized fibrotic eschar tissue formation.
The conclusions presented herein correspond with
clinical observations documented in the various cases
treated with preparation ISX2006.
Conclusions

Isx2006 clinical case presentation

Recommended

Recommended

More Related Content

Similar to Isx2006 clinical case presentation

Similar to Isx2006 clinical case presentation (20)

Recently uploaded

Recently uploaded (20)

Isx2006 clinical case presentation